Institute of Science Tokyo · School of Life Science and Technology · 助教

Research keywordscereblon neosubstrates・protein degraders・immunomodulatory drugs・multiple myeloma・pomalidomide activity・CRBN target discovery・HDAC Akt inhibitors・tumor immunotherapy

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders2022 · Chemical Society Reviews 2022年
• Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma2021 · Journal of Experimental & Clinical Cancer Research 2021年
• PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates2021 · Communications Biology 2021年
• Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells2021 · Molecular Cancer Therapeutics 2021年

• Cereblonの発現低下を伴うIMiDs耐性多発性骨髄腫に有効な治療標的の探索2023 · 研究課題/領域番号： 23K07807 2023年4月 - 2026年3月
• デキサメタゾンとIMiDsの相乗的な抗骨髄腫作用の分子メカニズムの解明2020 · 研究課題/領域番号： 20K08741 2020年4月 - 2023年3月

• Official profile